Eptifibatide

FDA Approved: * June 5, 2015
Pharm Company: * TEVA PHARMS USA
Category: Intravenous (IV) Therapy

Eptifibatide (Integrilin, Millennium Pharmaceuticals, also co-promoted by Schering-Plough/Essex), is an antiplatelet drug of the glycoprotein IIb/IIIa inhibitor class.[1] Eptifibatide is a cyclic heptapeptide derived from a disintegrin protein (P22827) found in the venom of the southeastern pygmy rattlesnake (Sistrurus miliarius barbouri). It belongs to the class of the arginin-glycin-aspartat-mimetics and reversibly binds to platelets. Eptifibatide has a short half-life. The ... [wikipedia]

* May have multiple approval dates, manufacturers, or labelers.

Dosage List

Eptifibatide 75 mg/100ml Intravenous Injection
NDC: 0338-9558
Labeler:
Baxter Healthcare Corporation
Eptifibatide 200 mg/100ml Intravenous Injection
NDC: 0338-9559
Labeler:
Baxter Healthcare Corporation
Eptifibatide 2 mg/ml Intravenous Injection, Solution
NDC: 0703-1165
Labeler:
Teva Parenteral Medicines, Inc.
Eptifibatide .75 mg/ml Intravenous Injection, Solution
NDC: 0703-1179
Labeler:
Teva Parenteral Medicines, Inc.
Eptifibatide 2 mg/ml Intravenous Injection
NDC: 14335-070
Labeler:
Hainan Poly Pharm. Co., Ltd.
Eptifibatide .75 mg/ml Intravenous Injection
NDC: 14335-071
Labeler:
Hainan Poly Pharm. Co., Ltd.
Eptifibatide .75 mg/ml Intravenous Injection, Solution
NDC: 16729-259
Labeler:
Accord Healthcare Inc.
Eptifibatide 2 mg/ml Intravenous Injection, Solution
NDC: 16729-260
Labeler:
Accord Healthcare Inc.
Eptifibatide 2 mg/ml Intravenous Injection, Solution
NDC: 17478-902
Labeler:
Akorn, Inc.
Eptifibatide .75 mg/ml Intravenous Injection, Solution
NDC: 17478-903
Labeler:
Akorn, Inc.
More Results

Related Brands

Drugs with the same active ingredients